MARKHAM, ON – January 26, 2026 – Cheelcare Inc. (“Cheelcare”), a Canadian innovator in advanced mobility solutions, announced today that it has received Pricing, Data Analysis, and Coding (PDAC) verification for its Companion power assist device, confirming eligibility for reimbursement under Medicare and Medicaid in the United States.

PDAC approval represents a critical milestone for clinicians, dealers, and wheelchair users, enabling Companion to be prescribed and funded based on clinical need rather than private-pay limitations. The approval allows Companion to be billed under HCPCS code E0986, aligning the device with standard Medicare funding pathways and simplifying access across the U.S. mobility ecosystem.

Enabling Better Clinical Decision-Making

For therapists and prescribers, PDAC approval removes a key barrier to recommending front-mounted power assist technology. Companion can now be incorporated more consistently into care plans to support endurance, joint preservation, and functional mobility to enhance Mobility-Related Activities of Daily Living (MRADLs)—without funding constraints limiting patient access. This is particularly impactful for users who benefit from power assist while maintaining the functional and lifestyle advantages of a manual wheelchair.

Simplifying Access for Dealers

For DME dealers, PDAC verification confirms that Companion meets Medicare’s requirements for coverage and reimbursement, reducing financial risk and enabling streamlined billing and fulfillment. Companion can now be offered alongside other reimbursable mobility solutions, supporting broader adoption within existing referral networks. Cheelcare currently supports Companion through a growing network of more than 300 authorized dealers across the United States.

Designed Around the End-User

Companion is purpose-built to be one of the most configurable and user-tailored front-mount power assist devices on the market. The system is designed to adapt to a wide range of users, environments, and clinical needs through:

• Extensive configurability, allowing the device to be tailored to individual mobility goals and functional abilities

• Multiple control options, including alternative controls for users with limited hand function

• Compatibility with both folding and rigid wheelchair frames, supporting a broad spectrum of wheelchair setups

• A compact, front-mounted form factor that preserves maneuverability and transportability without compromising performance

Companion also features a custom-designed tire engineered specifically for front-mount power assist applications, delivering optimized surface contact, improved traction, and non-marking performance across both within the home and within the community. Paired with Cheelcare’s SoftLaunch technology, which controls the initial acceleration of the motor to promote traction and reduce tire wear, this tire design supports predictable handling and consistent performance in daily use.

Built to Scale, Supported to Perform

To support growing demand following PDAC approval, Cheelcare has expanded its manufacturing and quality infrastructure, with operations now live at its new 16,000-square-foot facility. This investment ensures reliable production, serviceability, and long-term support for clinicians, dealers, and users alike.

“PDAC approval is essential for broad clinical adoption,” said Allan Boyd, Vice President of Growth at Cheelcare. “It allows therapists to prescribe Companion based on what is right for the user, gives dealers a clear reimbursement pathway, and makes our best-in-class power assist technology accessible to people who rely on Medicare and Medicaid.”

Cheelcare noted strong commercial momentum for Companion, with record assisted-device sales achieved in late 2025, reflecting growing demand ahead of broader reimbursement availability.